- Home
- BDC vs ACAD Comparison
BDC vs ACAD Comparison
Compare BDC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDC
- ACAD
- Stock Information
- Founded
- BDC 1902
- ACAD 1993
- Country
- BDC United States
- ACAD United States
- Employees
- BDC N/A
- ACAD N/A
- Industry
- BDC Telecommunications Equipment
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- BDC Telecommunications
- ACAD Health Care
- Exchange
- BDC Nasdaq
- ACAD Nasdaq
- Market Cap
- BDC 4.1B
- ACAD 3.5B
- IPO Year
- BDC 1993
- ACAD 2004
- Fundamental
- Price
- BDC $126.92
- ACAD $22.96
- Analyst Decision
- BDC Strong Buy
- ACAD Buy
- Analyst Count
- BDC 6
- ACAD 18
- Target Price
- BDC $128.50
- ACAD $27.94
- AVG Volume (30 Days)
- BDC 303.9K
- ACAD 1.8M
- Earning Date
- BDC 07-31-2025
- ACAD 08-06-2025
- Dividend Yield
- BDC 0.16%
- ACAD N/A
- EPS Growth
- BDC 1.04
- ACAD N/A
- EPS
- BDC 5.17
- ACAD 1.37
- Revenue
- BDC $2,550,165,000.00
- ACAD $996,283,000.00
- Revenue This Year
- BDC $8.74
- ACAD $13.28
- Revenue Next Year
- BDC $4.90
- ACAD $11.06
- P/E Ratio
- BDC $24.59
- ACAD $16.84
- Revenue Growth
- BDC 5.99
- ACAD 22.42
- 52 Week Low
- BDC $83.18
- ACAD $13.40
- 52 Week High
- BDC $131.82
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- BDC 63.83
- ACAD 61.44
- Support Level
- BDC $127.01
- ACAD $22.09
- Resistance Level
- BDC $130.50
- ACAD $23.60
- Average True Range (ATR)
- BDC 2.65
- ACAD 0.68
- MACD
- BDC 0.06
- ACAD 0.09
- Stochastic Oscillator
- BDC 71.04
- ACAD 79.17
About BDC Belden Inc
Belden Inc provides signal transmission products to distributors, end-users, installers, and original equipment manufacturers. The firm operates in two segments - Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions segment is a provider in network infrastructure and broadband solutions, as well as cabling and connectivity solutions for commercial audio/video and security applications. Automation Solutions segment provides network infrastructure and digitization solutions to enable customers to make data-based business decisions. It operates in Americas, EMEA and APAC, out of which maximum revenue from Americas.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.